Using ShockWAVE technology to treat severely calcified coronary artery disease

Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: A Randomized, Multicenter Study About the Additional Benefit of Coronary Lithotripsy

NA · Deutsches Herzzentrum Muenchen · NCT06369142

This study is testing a new technology called ShockWAVE to see if it can help people with severely calcified coronary artery disease get better results from stenting compared to standard methods.

Quick facts

PhaseNA
Study typeInterventional
Enrollment666 (estimated)
Ages18 Years and up
SexAll
SponsorDeutsches Herzzentrum Muenchen (other)
Locations22 sites (Heidelberg, Baden-Wurttemberg and 21 other locations)
Trial IDNCT06369142 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the efficacy and safety of intravascular lithotripsy (IVL) compared to traditional methods for preparing severely calcified coronary lesions before stenting. The study focuses on patients with significant coronary artery disease who have not responded adequately to optimal drug therapy. Participants will undergo procedures to assess the effectiveness of IVL in improving outcomes related to coronary interventions. The trial aims to provide insights into the economic benefits of using IVL in clinical practice.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with severe calcification in coronary lesions and evidence of ischemia.

Not a fit: Patients with recent myocardial infarction, significant thrombus in the target vessel, or limited life expectancy due to other diseases may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could improve treatment outcomes for patients with severely calcified coronary artery disease.

How similar studies have performed: Other studies have shown promising results with similar lithotripsy techniques, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. age ≥18 years and able to give informed consent
2. written informed consent to participate in the clinical trial
3. typical angina pectoris or non-invasive evidence of relevant ischemia under optimal drug therapy
4. angiographic evidence of coronary artery disease
5. de novo lesion in a native coronary artery
6. target vessel diameter 2.5-4 mm
7. severe calcification of the target lesion (angiographic grade 3)

Exclusion Criteria:

1. myocardial infarction \<1 week
2. thrombus in the target vessel
3. life expectancy due to other disease \<1 year
4. simultaneous participation in a clinical trial with medical devices or medicinal products that has not yet been completed
5. pregnancy (current, suspected, planned) or positive pregnancy test

Where this trial is running

Heidelberg, Baden-Wurttemberg and 21 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Coronary Artery Disease, Calcified lesion, Percutaneous Coronary Intervention, Stent, Intravascular Lithotripsy

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.